These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical and laboratory investigation of hematological malignancy patients carrying 3q21q26 rearrangement].
    Author: Xu FY, Liu XP, Qin S, Li CW, Lin D, Mi YC, Liu SH, Wang JX.
    Journal: Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec; 24(6):696-8. PubMed ID: 18067087.
    Abstract:
    OBJECTIVE: To investigate the clinical and laboratory characteristics of various hematopoietic malignant patients with t(3;3)(q21;q26) or inv(3) (q21q26). METHODS: Bone marrow samples were collected at presentation, prepared by short-time unstimulated culture and R-binding, and karyotyped by conventional cytogenetical assay (CCA); megalokaryocytes were detected by Streptavidin-AKP (SAP); immunotype of the leukemia cells was tested by flow cytometric anylysis of surface antigens (FACS). RESULTS: All of the 9 hematopoietic malignant patients with t(3;3)(q21;q26) or inv(3) (q21q26) manifested myelodysplasia and poor treatment response. One of them relapsed shortly after allogenic hemotopoietic stem cell transplantation (allo-HSCT). CONCLUSION: Patients with 3q21q26 rearrangement can be found in various hematopoietic malignances and demonstrate an unique entity. These patients show poor treatment response and have extremely poor prognosis.
    [Abstract] [Full Text] [Related] [New Search]